Keywords: genzyme, fabry, drug, france, under, atu, general
Genzyme Fabry drug in France under an ATU
Article | 22 January 2001
Genzyme General, a division of Genzyme Corp, has begun treating patientsin France with Fabrazyme (agalsidase beta) under an Authorisation Temporaire ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
